Etentamig

Phase 3Small molecule

AbbVie

Etentamig is one of 54 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Light Chain (AL) AmyloidosisNot yet recruiting

Relapsed/refractory Multiple MyelomaActive, not recruiting

Relapsed or Refractory Multiple MyelomaNot yet recruiting

Recurrent Waldenstrom MacroglobulinemiaRecruiting

Multiple MyelomaPhase 3

Active, not recruiting

Light Chain (AL) AmyloidosisPhase 3

Not yet recruiting

Relapsed/refractory Multiple MyelomaPhase 1

Active, not recruiting

Relapsed or Refractory Multiple MyelomaPhase 3

Not yet recruiting

Recurrent Waldenstrom MacroglobulinemiaPreclinical

Recruiting

Competition

Competitive Landscape

259 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

47 2

TALVEY

Johnson & Johnson

Phase 3

22 3

Keytruda

Merck & Co.

Phase 3

17 4

Venclexta

AbbVie

Phase 3

17 5

Opdivo

Bristol-Myers Squibb

Phase 3

11 6

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 7

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

22 8

Treanda

AAzurity Pharmaceuticals

Phase 3

19 9

Neulasta

Amgen

Phase 3

5 10

Vepesid

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Multiple Myeloma

NCT06223516

Phase 3Active, not recruiting

Multiple Myeloma

NCT06158841

Q3 2029

Phase 1Recruiting

Multiple Myeloma

NCT05650632

Q4 2030

PreclinicalRecruiting

Multiple Myeloma

NCT06953960

Q1 2033

Phase 3Not yet recruiting

Relapsed or Refractory Multiple Myeloma

NCT07728188

Clinical

Trials by Indication[1]

Multiple Myeloma8 trials

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT06223516·55 enrolled

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT06896916·135 enrolled

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT05286229·8 enrolled

Show 5 more trials

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06953960·325 enrolled

Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT07095452·680 enrolled

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06892522·602 enrolled

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Active, not recruiting· AbbVie logo

AbbVie·Phase 3·NCT06158841·421 enrolled

A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of Etentamig (ABBV-383) in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT05650632·210 enrolled

Recurrent Waldenstrom Macroglobulinemia1 trial

Phase 1/2 Trial of ABBV-383 for Patients With Relapsed Refractory Waldenström Macroglobulinemia

Recruiting·MMayo Clinic·Preclinical·NCT07420959·38 enrolled

Light Chain (AL) Amyloidosis1 trial

A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Not yet recruiting· AbbVie logo

AbbVie·Phase 3·NCT07793422·370 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT05259839·283 enrolled

Relapsed or Refractory Multiple Myeloma1 trial

A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)

Not yet recruiting· AbbVie logo

AbbVie·Phase 3·NCT07728188·520 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Etentamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Etentamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Etentamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Etentamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Q4 2030

Q1 2033

Trials by Indication[1]

Multiple Myeloma8 trials

Recurrent Waldenstrom Macroglobulinemia1 trial

Light Chain (AL) Amyloidosis1 trial

Relapsed/Refractory Multiple Myeloma1 trial

Relapsed or Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News